3/30/2022
Aachen, Germany, 30 March 2022 – Grünenthal, an international science-driven pharmaceutical company and a leader in pain therapy, has announced its full-year results for 2021. Net revenues reached €1.5 billion, an increase of 15 percent over 2020. Adjusted EBITDA reached €370 million, increasing by 10 percent compared to the prior year. Profitability was driven by robust sales growth, improved production efficiency, and strict cost management. Grünenthal's continued strong performance enabled the company to almost triple its adjusted EBITDA since 2017.